Breast Cancer(BC) And The Role of Circulating Tumor DNA
Keywords:
breast cancer, cancer diagnosis, ctDNA, liquid biopsy, personalized medicineAbstract
Immunohistochemistry is presently used to classify breast cancer. Nevertheless, breakthroughs in the monitoring of flowing tumor DNA (ctDNA) have opened up new avenues for diagnosis, categorization, biological understanding, and therapy selection. Thus, ctDNA tool further enhance our understanding the treatment. BC is a diverse illness, and ctDNA properly reflects this heterogeneity, enabling us to diagnose, monitor, and comprehend the disease's progression. Patients have greater circulating DNA levels than healthy persons, and ctDNA can be employed for a variety of purposes at various stages of disease, from advance screening diagnosis for advance disease. ctDNA is present in higher patients and can be used to detect mutations with the disease. It can also be used to monitor the progression of the disease and to detect mutations in advanced cases. The use of genetic testing in cancer diagnosis has grown significantly. It may be used to identify genetic changes linked to certain forms of cancer, allowing clinicians better understand the condition and determine the best course of action for their patients. This enables earlier and more accurate diagnosis as well as more intelligent treatment choices. Better rates of a full pathological response after neoadjuvant therapy and fewer cases after radical treatments have been associated with ctDNA in early breast cancer.
References
Mathelin C, Ame S, Anyanwu S, Avisar E, Boubnider WM, Breitling K et al. Breast cancer management during the COVID-19 pandemic: the senologic international society survey. Eur J Breast Health. 2021 Apr;17(2):188-96. doi: 10.4274/ejbh.galenos.2021.2021-1-4, PMID 33870120.
Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Ulas A et al. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. J BUON. 2015 Jan 1;20(1):45-9. PMID 25778295.
Poudineh M, Sargent EH, Pantel K, Kelley SO. Profiling circulating tumour cells and other biomarkers of invasive cancers. Nat Biomed Eng. 2018 Feb;2(2):72-84. doi: 10.1038/s41551-018-0190-5, PMID 31015625.
Li S, Yi M, Dong B, Tan X, Luo S, Wu K. The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. Int J Cancer. 2021 Jun 1;148(11):2640-51. doi: 10.1002/ijc.33386, PMID 33180334.
Chapin WJ, Till JE, Hwang WT, Eads JR, Karasic TB, O’Dwyer PJ et al. Multianalyte prognostic signature including circulating tumor DNA and circulating tumor cells in patients with advanced pancreatic adenocarcinoma. JCO Precis Oncol. 2022 Aug;6:e2200060. doi: 10.1200/PO.22.00060, PMID 35939771.
Conceição F, Sousa DM, Paredes J, Lamghari M. Sympathetic activity in breast cancer and metastasis: partners in crime. Bone Res. 2021;9(1):9. doi: 10.1038/s41413-021-00137-1, PMID 33547275.
Haselmann V, Ahmad-Nejad P, Geilenkeuser WJ, Duda A, Gabor M, Eichner R et al. Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). Clin Chem Lab Med. 2018 Feb 1;56(2):220-8. doi: 10.1515/cclm-2017-0283, PMID 28841569.
O’Leary B, Hrebien S, Beaney M, Fribbens C, Garcia-Murillas I, Jiang J et al. Comparison of BEAMing and droplet digital PCR for circulating tumor DNA analysis. Clin Chem. 2019 Nov 1;65(11):1405-13. doi: 10.1373/clinchem.2019.305805, PMID 31551314.
Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K. Changes in concentration of DNA in serum and plasma.
Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K. Changes in concentration of DNA in serum and plasma during Storage of Blood Samples. Clin Chem. 2003;49(6 Pt 1):1028-9. doi: 10.1373/49.6.1028, PMID 12766024.
Garcia J, Forestier J, Dusserre E, Wozny AS, Geiguer F, Merle P et al. Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR BioRad detection assay, BEAMing assay, and NGS strategy). Oncotarget. 2018 Apr 4;9(30):21122-31. doi: 10.18632/oncotarget.24950, PMID 29765524.
Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021 Dec 1;161:98-105. doi: 10.1016/j.yjmcc.2021.07.004, PMID 34298011.
Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ; et al.
Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021, PMID 26311728.
Jiang M, Li CL, Luo XM, Chuan ZR, Lv WZ, Li X et al. Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer. Eur J Cancer. 2021 Apr 1;147:95-105. doi: 10.1016/j.ejca.2021.01.028, PMID 33639324.
Dong M, Shan B, Han X, Zhao X, Wang F, Zhu L et al. Baseline mutations and up-regulation of PI3K-AKT pathway serve as potential indicators of lack of response to neoadjuvant chemotherapy in stage II/III breast cancer. Front Oncol. 2022 Apr 4;11:5898.
Rodriguez BJ, Córdoba GD, Aranda AG, Álvarez M, Vicioso L, Pérez CL et al. Detection of TP53 and PIK3CA mutations in circulating tumor DNA using next-generation sequencing in the screening process for early breast cancer diagnosis. J Clin Med. 2019 Aug 7;8(8):1183. doi: 10.3390/jcm8081183, PMID 31394872.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr S. Parthasarathy
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
